Leading tennis players train two to three hours a day to prepare for tournaments and have daily coaching input to make them game ready.
It’s a gruelling regime but the rewards are obvious. Competing at the top level in pharma sales could be developed by following in the fast footsteps of Roger Federer and Rafael Nadal.
Experts believe time spent practising delivery and messaging will reap dividends providing it is grooved into a sales force or medical science liaison (MSL) team’s schedule.
Digital tools provide a flexibility that means coaching in the pharmaceutical industry doesn’t reach the exhausting levels of tennis and other sport. But consistency is the key to progression and results.
The retreat from face-to-face engagements has placed extra pressure on sales and MSLs who now have to make sure every precious moment with HCPs is laden with understanding and value.
“Coaching is what will ultimately drive the bottom line and the overall results, so it has to be highly valued,” observes Michael Cassar, regional sales manager at Galderma, who has a track record with pharmaceutical multi-nationals such as Wyeth, GSK, MSD and Liberty Medical.
“Coaching needs to be a constant, a daily event not an ad hoc, box-ticking exercise such as doing a bit of role playing and coaching around sales skills when a conference is coming up.”
A new whitepaper – The Age of Coaching: How pharma sales teams can face the future with confidence – highlights how empowering a coaching culture and ring-fencing its time and resources can generate huge rewards.
“It has to be regular and ring-fenced and the way an organisation demonstrates it values coaching is by allocating time to it rather than approaching it as an afterthought. Coaching also has to come with timely, constructive feedback if you want to improve or change performance.
“Roger Federer, Michael Jordan and the best athletes in the world trained hard but they also had coaches who provided feedback.”
Interactions between field representatives and HCPs withered during the pandemic and, although the face-to-face frost is gradually thawing, they will remain hard-won and probably shorter than pre-pandemic as clinicians deal with mounting pressures. An organisation’s messages and value need to land first time with first serve accuracy.
But coaching still suffers from a bolt-on mentality and studies across sales reps of all sectors indicate that provision is still distant from need – the Voice of the Sales Rep Study, from SalesFuel in 2020, reported that only 30% of reps get frequent coaching personalised to their unique needs.
Fear of disruption and capital costs may be a factor to commissioning a new coaching culture, but it should be neither expensive nor difficult to develop, comments Emma Booth, executive director global business at Amgen.
‘It can seem an unimaginable task to fit coaching into already busy and crowded timetables but if you break it down and have coaching in your weekly kind of catch up, then I think it can become more readily adopted,’ she says.
The pharma market is getting busier with a procession of biotech product launches and feverish activity across the orphan disease sector so sales and MSLs must be at the top of their game to ensure they can land real value when they connect with HCPs via in-person, virtual or digital engagements.
‘These are high value moments and preparing for them should be a prime objective,’ says Marcus West, founder and CEO of 60 Seconds, the leading remote coaching app. ‘Being able to approach a meeting with the confidence that your science, knowledge, and messaging work is a distinct advantage in terms of staff confidence and positive impact.
‘These moments are getting rarer, so organisations need to deliver peak performance at the right time. You get that by consistent coaching, not episodic events, or last-minute efforts on the way to meetings.”
About the interviewees
Emma Booth is executive drector global business process and insights lead, R&D strategy and operations at Amgen. Emma is a highly experienced and professional people-development strategist. She has worked in variety of medical affairs roles at Amgen Europe for the past 13 years. She is people-focused from both a team development and skills building perspective; as well as organisational design and implementation of technological solutions and process development.
Chris Costandi is a sales and commercial excellence consultant at 60 Seconds. He has worked in the Healthcare industry for over 20 years across a variety of divisions including prescription, medical devices and OTC for organisations such as Allergan, Novartis and GSK in driving a range of transformational sales force effectiveness (SFE) initiatives including capability development, coaching and leadership and key account management.
Michael Cassar is regional sales manager at Galderma. Michael has an extensive background as a senior sales manager in the pharmaceutical and medical device industries across ANZ at Wyeth, GSK, MSD, Liberty Medical, Indivior and Galderma . He has worked with many teams to drive superior results in primary care, hospital, specialty, OTC, and devices. With a background in human movement and skill acquisition, Mike’s core expertise is coaching and mentoring his direct reports on their ongoing development and driving a customer engagement mindset.
About 60 Seconds
60 Seconds is a remote coaching app designed to help users communicate with greater clarity through practice, coaching and measurement. It was built by a coach for coaches to deliver measurable learning momentum. For more information visit: 60seconds.com
The post Coaching Consistency appeared first on .otc pandemic europe
Why Is The VIX So Low? A Surprising Answer Emerges In The Market’s Microstructure
Why Is The VIX So Low? A Surprising Answer Emerges In The Market’s Microstructure
One of the most frequent questions tossed around Wall Street…
One of the most frequent questions tossed around Wall Street trading desks (and strip clubs), and which was duly covered by Bloomberg recently in "Fear Has Gone Missing in Wall Street’s Slow-Motion Bear Market", is why despite the crushing bear market and the coming recession, does the VIX refuse to rise sustainably above 30, or in other words, why is the VIX so low?
As Goldman's Rocky Fishman wrote in a recent note "Option Markets Take the SPX Bear Market in Stride" (available to professional subs), "one of the most popular questions we have received is why the VIX hasn't surpassed its March peak (36) despite the SPX being lower than it was in March and realized vol being higher than it was in March."
Here, Fishman notes that implied volatility was unusually high in March, and the current VIX level (29) is only slightly low for the current level of realized vol. Furthermore, a VIX around 30 typically happens with the 5Y CDX HY spread above 600, and although it has risen steadily it's currently in the mid 500's.
Meanwhile, even as the VIX has fallen moderately since late April, both vol risk premium and skew have both fallen dramatically.
Picking up on this quandary, overnight JMorgan also joined the discussion with its analyst Peng Cheng laying out his own thoughts on why the VIX remains so low (note is also available to professional subs), and similar to Goldman notes that the current bear market, despite being deeper in magnitude, has produced VIX levels well below the peak observed during previous market sell-offs:
However, unlike Goldman which mostly analyzes the VIX in the context of a macro framework, JPM's Cheng offers observations based on his analysis of market microstructure in both equity and options markets.
Cheng starts with the previously noted low realized volatility: as the JPM strategist writes, YTD, the SPX realized vol, measured on a close to close basis, is only 25.5, which means that delta-hedged put options would have lost money in the gamma component. From a technical perspective, JPM believes that return volatility is dampened by a lack of intraday price momentum and increasingly frequent occurrences of intraday price reversal. As seen in the next chart, intraday reversal has only started to become noticeable in the last two years. Prior to that, intraday momentum was the dominant market behavior.
This diminishing intraday price momentum has had a non-trivial impact on realized volatility, according to JPM which estimates that if the intraday return correlation remained the same as pre-pandemic, YTD volatility would be close to 28.8, or 3.3 vol points higher than realized.
As an aside, those asking for the reason behind this change in intraday patterns in the last couple of years, Cheng notes that "this is a complex topic" but in short, his view is that it is a result of 1) crowding in intraday momentum trading strategies and 2) a potential shift in option gamma dynamics as discussed below.
Supply/demand of S&P 500 options: Although the estimation of market level option gamma profile is highly dependent on many factors, including assumptions on open interest, OTC options, and leveraged ETFs, etc., in a report published earlier this year, JPM's quants presented a more dynamic estimation of the gamma profile by using tick level data. Specifically, they assigned directions to SPX and SPY option trades based on their distance to the best bid/offer at the tick level, rather than the constant assumption of investors being outright long puts and short calls. The updated results are shown below.
Tha chart shows that starting in 2020, the put gamma imbalance has fallen meaningfully. This is the result of investors’ changing preference from buying outright puts to put spreads for protection, in JPM's view. And year to date, the decline in gamma demand has not improved. Moreover, and echoing what we have said on several recent occasions, JPM notes that judging from the outright negative put gamma imbalance in early 2022, it appears that investors have been monetizing hedges that had been held since 2021 - note the consistently positive and relatively elevated put gamma imbalance throughout 2021, which suggests that protections were put on during this period.
More in the full note available to pro subs
Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving
Penny stocks to watch with news
The post Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving appeared first on Penny Stocks to…
Penny stocks are well-known for their high-risk and high-reward potential. When it comes to a choppy stock market, traders will flock to some of these names for quick gains instead of taking a chance at investing in a broader market that still has some downside left.
Needless to say, this week, in particular, could bring more speculation and uncertainty thanks to key economic data. The foremost is second-quarter GDP results set to report on Wednesday. The biggest question is, will GDP data signal signs or even confirm a recession?
According to the Bureau of Economic Analysis, the figures show some interesting trends:
“Real gross domestic product (GDP) decreased at an annual rate of 1.5 percent in the first quarter of 2022, following an increase of 6.9 percent in the fourth quarter of 2021. The decrease was revised down 0.1 percentage point from the “advance” estimate released in April. In the first quarter, there was a resurgence of COVID-19 cases from the Omicron variant and decreases in government pandemic assistance payments.”
But whether or not this read-out is bullish or bearish may not matter much to traders looking for penny stocks to buy. Let’s explain.
Penny Stocks To Watch
In general, broader market trends take a back seat to whatever individual catalysts are at play with penny stocks. If you’ve traded long enough, I’m sure you’ve seen the stock market crash lower, yet several penny stocks are exploding higher. This detached trend is unique and has become one of many reasons traders hunt for top trending penny stocks daily.
One of the most prominent reasons for cheap stocks to move iradically even with the stock market down tends to involve headlines. These can become significant catalysts for a bullish (or bearish) trend. Here’s a quick list of penny stocks with news that are moving during the week.
- Wejo Group Limited (NASDAQ: WEJO)
- Bird Global Inc. (NYSE: BRDS)
- Tuniu Corp. (NASDAQ: TOUR)
- JanOne Inc. (NASDAQ: JAN)
- Endo International (NASDAQ: ENDP)
Best Penny Stocks To Buy Now
Are penny stocks with news the best to buy now? Much of that answer deals with specific trading styles. Sometimes, news catalysts can be short-lived, primarily suitable for day traders. In other instances, headlines include verbiage and further discussion that prompt a longer-term forecast for some. If a company posts news, diving deeper beyond the headline is a good idea.
Wejo Group Limited (NASDAQ: WEJO)
Who said penny stocks have no legitimate business with well-established companies? Wejo Group is a prime example of why that statement isn’t accurate. The smart-mobility could solutions company focuses on electric and autonomous vehicle data. This has become a point of interest for those looking at car companies aiming for self-driving and a more tech-focused model.
Why WEJO Stock Is Moving
This week, Wejo Group announced a collaboration with none other than Ford Motor Company (NYSE: F) in Europe. The two will leverage data and insights where Wejo can access personalized connected vehicle data from Ford vehicles.
“Providing actionable data insights to insurance providers is another example of how Wejo is expanding into additional markets and demonstrating new use cases for OEMs and insurance companies to monetize connected vehicle data for good,” said Richard Barlow, founder, and CEO, of Wejo.
Bird Global Inc. (NYSE: BRDS)
Another mobility company on the list of penny stocks to watch is one you might have seen “scooting” around your city. Bird Global offers eScooters and eBikes that anyone can rent using a Bird-connected app. Billing itself as a “micro electric vehicle company,” Bird’s suite of scooters and bikes is becoming popular among riders looking for urban travel without getting in an actual vehicle. Unfortunately, BRDS stock wasn’t such a high flyer after its IPO debut last year. Shares have gone from highs of $11.25 to lows of $0.4648 in a matter of 7 months.
Why BRDS Stock Is Moving
Earlier this month, Bird received a notice of non-compliance with the NYSE based on its low share price. The exchange requires companies to maintain a closing price of at least $1 for 30 consecutive trading days to keep the listing. Considering that the company plans to notify the NYSE by July 5th of its intention to “cure” the stock price deficiency, there could be some speculation building as the countdown begins.
Tuniu Corp. (NASDAQ: TOUR)
Travel is one of the industries taking a back seat over the last few years. Thanks to the rise of the pandemic and continued COVID restrictions, travel stocks haven’t faired as well as their market cohorts. However, the area of the industry that has remained beaten down involves companies with exposure to China’s market.
Tuniu Corp. is a prime example of the bearish sentiment for Chinese travel stocks. TOUR stock has slumped from over $2 to under $0.50 within the last year. The company offers an online leisure travel service focused on prepackaged and self-guided tours. This week, TOUR stock’s tides changed a bit, and shares have begun to rally.
Why TOUR Stock Is Moving
There isn’t any TOUR stock-specific news. However, broader industry information has come to light and acted as a catalyst. In particular, China has begun loosening its COVID quarantine rules. As a result, bullish sentiment has returned to the sector, prompting momentum in several travel names, including Tuniu.
JanOne Inc. (NASDAQ: JAN)
JanOne develops drugs with non-addictive and pain-relieving properties. One of its focuses is on curbing the opioid crisis. Its JAN101 platform is being developed for treating peripheral artery disease and is a catalyst behind the latest move in JAN stock today.
Why JAN Stock Is Moving
This week, JanOne announced that work was completed with Dr. Maureen Donovan at the University of Iowa. It will allow for an improved formulation of JAN101, which has been used successfully in trials for reducing pain and improving nerve function. Furthermore, JanOne expects to start manufacturing and validating processes “in the near future.”
One of the other attractive points of interest for traders is JAN stock’s float. Looking at multiple outlets, you’ll see that this figure is well below 10 million shares. In cases of low float penny stocks, volatility can play a leading role. Given the latest headline, this could be something to keep in mind heading into the rest of the week.
Endo International (NASDAQ: ENDP)
Shares of Endo International took flight this week. The specialty pharmaceutical company recently focused on developing an orthopedic product for treating osteoarthritis knee pain. It signed a deal with Taiwan Liposome to commercialize its TLC599 injectable compound, which is in Phase 3 development for osteoarthritis treatment.
“TLC599 is fully aligned with our commitment to providing differentiated nonsurgical options to healthcare providers and their appropriate patients,” said Patrick Barry, Executive Vice President, and President, Global Commercial Operations at Endo, in a June 13th update.
Why ENDP Stock Is Moving
You won’t find anything in corporate newsfeeds if you’re looking for why ENDP stock is moving right now. However, if you dig deeper into the company’s filings, there may be something evident acting as a catalyst in the stock market today. Millennium Management LLC filed a 13G on June 27th, showing a 1.7% stake in the company. In our article Buy Penny Stocks Like Hedge Funds Do: A How-To Guide, we discussed specific forms and filings to pay attention to if you want to “follow” the money of investment firms.
A 13G pertains to “passive investors” owning less than 20% of a company’s outstanding shares. Once a “passive investor” reaches over 20% of the OS, they must start filing 13D statements.
Best Penny Stocks Today
News can be a way to find names for your penny stocks list. However, when it’s time to buy them, it’s best to dig a little deeper to determine if that news has lasting potential. Penny stocks with news experience volatility early. When it comes to follow-through, much of that comes down to the market itself. Today we looked at 5 penny stocks with news, industry-related speculation, or corporate developments. After seeing why they moved, are any on your watch list right now?
If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!recession pandemic covid-19 nasdaq stocks penny stocks treatment quarantine gdp europe china
Hot Penny Stocks to Buy This Week? 3 For Your List
Can these penny stocks continue to climb
The post Hot Penny Stocks to Buy This Week? 3 For Your List appeared first on Penny Stocks to Buy, Picks, News…
3 Hot Penny Stocks to Add to Your Watchlist This Week
Let’s face it, finding penny stocks to buy is not easy. And over the past few months, it has been increasingly challenging to make money with small caps. Now, while this may be true, not every investor has lost money in that time. Rather, to make money with penny stocks, traders have to be extra careful and know what penny stocks to buy.
There are a few key things to look for when finding penny stocks to buy. The first is a reason that it may move. When penny stocks shift up or down, there are numerous causes. But, most penny stocks will have a fundamental reason to do so. This could be a new product launch, an FDA approval, or anything else that would increase demand for the company’s shares.
The second is liquidity. This is key because you need to be able to buy and sell penny stocks quickly. If there is not enough liquidity or shares traded in a day, you may be stuck with your penny stock.
The last is price. You obviously want to buy penny stocks that are cheap, but you also want to make sure that the company is valued appropriately. This means looking at its fundamentals and understanding why it is at its given value. With all of this in mind, let’s take a look at three penny stocks to add to your watchlist this week.
3 Penny Stocks to Watch This Week
- Visionary Education Technology Holding Group Inc. (NASDAQ: VEDU)
- RLX Technology Inc. (NYSE: RLX)
- Uranium Energy Corp. (NYSE: UEC)
Visionary Education Technology Holding Group Inc. (NASDAQ: VEDU)
One of the largest gainers of the day on June 27th was VEDU stock. By EOD, shares of VEDU had shot up by more than 30% with an over 5% after-hours gain. And, in the past five days, shares of VEDU stock have exploded by over 120%. These major gains come alongside no recent news. The most recent news however, came on May 19th.
On the 19th, the company announced the closing of its $17 million firm commitment IPO. This came with 4.25 million shares at a public offering price of $4 per share. For some context, Visionary Education is a Canadian based company offering high-quality education resources to students around the world. While it has fallen from its IPO price to around $2.60, its recent bullish momentum is exciting without a doubt. So, with all of this in mind, will VEDU be on your penny stocks watchlist or not?
RLX Technology Inc. (NYSE: RLX)
With over 3% in gains during trading and after hours on June 27th, RLX is another penny stock that investors are watching right now. In the past month, we’ve seen shares of RLX climb by more than 19%, which is no small feat. The most recent news from the company came in the form of its unaudited Q1 2022 financial results. In the results, the company saw its net revenue decline slightly, however, it stated that this was due to the pandemic.
“During the first quarter of 2022, we continued to focus on our core strategy and maintain our leading position in the industry while preparing for the anticipated regulatory changes.
As the new regulatory framework has come into effect and detailed implementation measures have been released, we are proactively adapting our business to the new market environment by applying for the relevant licenses and developing qualified products that meet the requirements of the most recent national standards.”The CEO of RLX Technology, Ms. Ying Wang
While this news was not ideal, it did bring shares of RLX stock down to lower levels. And as a result, its recent bullish momentum could be due to RLX being at value prices. Whether this makes RLX worth adding to your list of penny stocks to buy, is up to you.
Uranium Energy Corp. (NYSE: UEC)
On June 27th, UEC stock saw modest gains however, it did post abnormally high volume. And because of this, many investors are keeping a close eye on it right now. The most recent update from the company came on June 22nd, when it announced its entrance into a definitive agreement with UEX Corporation. It stated that it would acquire all of the outstanding shares of UEX with a C$5 million private placement.
This is big news for the company and should add to its large and growing business. If you’re not familiar, Uranium Energy is a uranium mining company. And, recently, we’ve seen heightened interest in alternative energy penny stocks. And although UEC is highly volatile, it is an interesting penny stock to watch. With this considered, does UEC deserve an addition to your watchlist or not?
Which Penny Stocks Are You Buying Right Now?
After a relatively flat day of trading, investors are looking for the best penny stocks to buy this week. That involves understanding what factors are impacting the stock market, and how we can use those to benefit.
Although trading is not easy, there are plenty of ways to find penny stocks to buy in 2022. So, with this in mind, which penny stocks are you buying right now?
The post Hot Penny Stocks to Buy This Week? 3 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.nasdaq stocks pandemic penny stocks fda small caps
Shedding light on reptilian health: Researchers investigate origins of snake fungal disease in U.S.
Escobar: Behind The Tin Curtain – BRICS+ Vs NATO/G7
The Depopulation Of Taiwan
FTSE 100 gains as commodity-linked stocks bounce back
ECB To Launch “First Line” Of Bond Crash Defense On Friday, Same Day QE Ends
Gilead tries again with twice-yearly HIV drug lenacapavir
How prepared is biopharma for the cyber doomsday?
No sign of major crude oil price decline any time soon
China Suggests It Could Maintain ‘Zero COVID’ Policy For 5 Years
Is it safe to buy WTI crude oil after bouncing from horizontal support?
Spread & Containment21 hours ago
Escobar: Behind The Tin Curtain – BRICS+ Vs NATO/G7
Economics5 hours ago
NEVADA SUNRISE CLOSES $1,500,000 PRIVATE PLACEMENT
Economics12 hours ago
Waste management plan: Encouraging 2021 Results to Achieve Objectives
Economics19 hours ago
Winners and losers in this volatile housing market
Government21 hours ago
Social Media Study Shows Growing DeSantis Boom Among Swing Voters
Science7 hours ago
Emergent Health (OTCMKTS: EMGE) Up Big and Getting Noticed by Investors After Biotech Signs LOI to Acquire Fusion Specialty Pharmacy
International14 hours ago
How Representative Is The G7 Of The World It’s Trying To Lead?
Government8 hours ago
White House Is Quietly Modeling For $200 Oil “Shock”